OVCAR8 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	OVCAR-8 is a human ovarian cancer cell line derived from a 64-year-old female patient with high-grade serous ovarian adenocarcinoma. The cells grow as an adherent epithelial-like monolayer and typically double in approximately 24-32 hours under commonly used conditions. OVCAR-8 carries a homozygous TP53 splice-acceptor alteration together with heterozygous CTNNB1, ERBB2, and KRAS variants and has a microsatellite-stable phenotype. Its extensive genomic, transcriptomic, proteomic, metabolomic, drug-response, and functional-screening datasets support studies of ovarian cancer biology, treatment response, DNA damage, signaling, invasion, and therapeutic vulnerabilities.
Cell Type	Human ovarian carcinoma epithelial cell
Tissue	Ovary
Disease	High-grade ovarian serous adenocarcinoma
Gender	Female
Age	64 years
Population Background	Predominantly European genomic ancestry
Morphology	Epithelial-like cells forming an adherent monolayer
Growth Mode	Adherent
Applications	1. High-grade serous ovarian cancer research 2. Ovarian cancer proliferation, survival, and signaling studies 3. TP53 splice-variant and p53-pathway research 4. CTNNB1, ERBB2, and KRAS pathway studies 5. Platinum and taxane response research 6. Glutathione metabolism and oxidative-stress studies 7. DNA-damage response and radiosensitivity assays 8. Migration, invasion, spheroid, and metastatic-growth studies 9. Cell viability, apoptosis, clonogenic, and drug-combination assays 10. CRISPR, RNA interference, and functional-genomics screens 11. Genomic, transcriptomic, proteomic, and metabolomic profiling 12. Xenograft tumor-growth and preclinical treatment studies
Characteristics
Histologic Classification	High-grade serous ovarian adenocarcinoma model
TP53 Alteration	Homozygous TP53 c.376-1G>A splice-acceptor variant, producing an in-frame deletion of amino acids Tyr126 through Lys132
CTNNB1 Variant	Heterozygous CTNNB1 c.77A>G, producing p.Gln26Arg (Q26R)
ERBB2 Variant	Heterozygous ERBB2 c.2327G>T, producing p.Gly776Val (G776V)
KRAS Variant	Heterozygous KRAS c.362C>A, producing p.Pro121His (P121H)
Microsatellite Status	Microsatellite stable
Platinum Response	OVCAR-8 shows comparatively high cisplatin resistance in multi-line panels, with increased glutathione synthesis associated with the resistant phenotype. Treat drug response as assay-, exposure-, and culture-dependent rather than as a fixed clinical prediction.
Tumorigenicity	Forms tumors in immunodeficient mouse models after subcutaneous or intraperitoneal implantation.
Mycoplasma Test	Negative
Culture Conditions and Handling
Culture Conditions	37°C in a humidified atmosphere containing 5% CO₂
Culture Surface	Standard tissue-culture-treated vessels for routine monolayer propagation
Medium Renewal	Two to three times per week, adjusted to cell density and experimental design
Dissociation Reagent	0.25% trypsin containing EDTA
Dissociation Time	Approximately 2–3 minutes at 37°C; monitor detachment microscopically and stop digestion promptly
Split Ratio	1:3 to 1:4 for routine propagation
Subculturing	1. Passage healthy cultures before prolonged overconfluence. 2. Remove the spent medium and rinse the monolayer with calcium- and magnesium-free PBS. 3. Add enough 0.25% trypsin–EDTA to cover the cell layer. 4. Incubate at 37°C and monitor rounding and detachment microscopically. 5. Add complete serum-containing medium to stop dissociation. 6. Collect the suspension and gently disperse aggregates. 7. Seed fresh vessels at a 1:3 to 1:4 ratio in complete RPMI-1640. 8. Return cultures to 37°C and 5% CO₂ and verify attachment and epithelial-like morphology.
Cryopreservation	Harvest an actively growing culture, prepare a uniform viable-cell suspension, and resuspend the cells in a validated cryopreservation medium. Dispense into labeled cryovials, cool at a controlled rate, and transfer to liquid nitrogen for long-term storage.
Long-Term Storage	Liquid nitrogen at approximately −150°C to −196°C; use −80°C only for short interim storage
Thawing	Rapidly thaw the vial at 37°C, disinfect the exterior, dilute the suspension with pre-warmed complete medium, and remove residual cryoprotectant according to the local recovery workflow. Seed into a suitable vessel and confirm attachment, morphology, and growth before experimental use.
Handling Notes	Use aseptic technique and handle the culture as human-derived research material under an appropriate local risk assessment. Record passage number, confluence, serum lot, medium formulation, and time after seeding.

Cat.No.	Product Name	Price
CSC-RR0468	GFP Stable Cell Line - OVCAR8	Inquiry
CSC-RR0546	Luciferase Reporter Cell Line - OVCAR8	Inquiry
CSC-RO01633	OVAL Stable Cell Line - OVCAR8	Inquiry
CSC-RO01886	GFP/OVAL Stable Cell Line - OVCAR8	Inquiry
CSC-RO02139	Luc/OVAL Stable Cell Line - OVCAR8	Inquiry
CSC-RO02392	GFP/Luc/OVAL Stable Cell Line - OVCAR8	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry